Roche Diagnostics has welcomed a communication from the Indian Council of Medical Research to states asking them to conduct seroprevalence studies for COVID19 in India.
“Roche Diagnostics India welcomes ICMR’s communication that cites making available Roche COVID-19 antibody test for seroprevalence studies in India – including those on high-risk groups like healthcare workers – to plan the country’s pandemic management efforts in the future. Roche’s lab-based antibody test that runs on fully automated CLIA analysers with estimated peak testing capacity of 0.5 million tests a day is being made available across NABL approved and Government sites in India,” said Dr Shravan Subramanyam, spokesperson for Roche Diagnostics India.
ICMR has communicated a detailed plan to all the states to measure coronavirus exposure in general population as well as in high risk populations.
In an attempt to decide the future course of action against the pandemic, ICMR has communicated a detailed plan to all the states to measure coronavirus exposure in general population as well as in high risk populations. This sero-survey will guide appropriate public health intervention. The numbers and frequency in different groups to be tested has been entrusted with states depending upon the requirement and situation in that particular area.
“The Roche Elecsys Anti-SARS-CoV-2 serology test that supports detection of antibodies against SARS-CoV- 2 has received the Import License issued by the Central Drug Standard Control Organization (CDSCO), due to the emergency health situation in the public interest. The test is CE IVD certified and has received USFDA emergency use authorisation (EUA). Roche’s world-class COVID-19 antibody test is already deployed in UK, Singapore and other countries to test for COVID-19 antibodies. We are committed to explore public-private partnerships to build scale and thereby access to Roche COVID- 19 antibody tests in India,” Roche added.